Combination therapy provides similar clinical benefit as single drug treatment in MS

Drugs taken together do not reduce risk of relapse but appear to prevent development of new lesions

2013-03-11

(Press-News.org) People with multiple sclerosis (MS) who were treated with combination therapy did not see significant clinical benefit over those treated with single drug therapy, but combination therapy did reduce the development of new lesions, according to an international research team led by The Mount Sinai Medical Center. The findings, part of the largest-ever MS trial sponsored by the National Institutes of Health, are published in the March 11 issue of Annals of Neurology.

In the Phase III CombiRx trial, researchers led by Fred Lublin, MD, of The Mount Sinai Medical Center, sought to determine if Glatiramer Acetate (GA) and Interferon Beta-1a (IFN), the two most commonly-prescribed drugs for relapsing-remitting MS (RRMS), were more effective in combination than as monotherapies. The results showed that while combination therapy was no better than monotherapy, patients who took combination therapy had a reduction in new lesions on MRI scan.

"This is the first NIH-sponsored, multi-center, comparative trial evaluating the benefits of both combination therapy and monotherapy in MS," said lead author Fred Lublin, MD, Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at The Mount Sinai Medical Center. "The study is the first to show that a combination trial is feasible in MS, to compare a combination to established monotherapy, and to provide comparative efficacy data for two commonly-prescribed drugs."

The research team enrolled 1,008 participants from 68 sites to receive IFN plus GA (499), IFN alone (250), or GA alone (259), with 30µg IFN administered intramuscularly weekly and/or 20 mg of GA injected daily. The groups were followed for three years to assess if the combination therapy reduced MS relapse rates.

While combining IFN and GA was safe and effective, patients taking this regimen did not see clinical benefit greater than those taking a single agent. There was no substantial improvement in neurological function in participants in the combination therapy group. They also found that GA alone was superior to IFN alone in reducing relapse rates. MRI findings also suggested that the IFN plus GA together were better in reducing new lesions and total lesion accumulation than either drug alone.

"While there was no substantial clinical benefit of combination therapy over monotherapy, we will continue to monitor these patients to see if the reduction in MRI lesion translates into a future clinical benefit," said Dr. Lublin. "The CombiRx study also provides a large dataset to analyze different aspects of the disease, such as potential biomarkers for prognosis and response to therapy."

The National Institute of Neurological Disorders and Stroke (NINDS) provided funding for the CombiRx clinical trial (grant #UO1NS045719 and R21NS41986), which will continue to evaluate the cohort for four more years.

"The investigators were successful in implementing a clinical trial comparing the effectiveness of a two-drug combination to treatment with a single drug," said Petra Kaufmann, MD, MSc, Associate Director for Clinical Research, NINDS. "The trial answered an important question to the MS community: The results did not show a clinical benefit in people taking two drugs rather than one drug. In addition to answering this question, the trial has resulted in valuable clinical and imaging observations that can help researchers to better understand the course of MS and that can inform the planning of future trials."

The NINDS describes MS as a neuroinflammatory disease, which affects the central nervous system by attacking myelin, a substance found in nerve fibers, and causing lesions. NINDS estimates that up to 350,000 individuals in the U.S. have MS, which affects twice as many women as men, with most symptoms appearing between the ages of 20 and 40. Experts believe this complex autoimmune disease may be caused by genetic and environmental factors.

### About The Mount Sinai Medical Center

The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Icahn School of Medicine at Mount Sinai. Established in 1968, the Icahn School of Medicine at Mount Sinai is one of the leading medical schools in the United States. The Icahn School of Medicine is noted for innovation in education, biomedical research, clinical care delivery, and local and global community service. It has more than 3,400 faculty members in 32 departments and 14 research institutes, and ranks among the top 20 medical schools both in National Institutes of Health (NIH) funding and by U.S. News & World Report.

The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation's oldest, largest and most-respected voluntary hospitals. In 2012, U.S. News & World Report ranked The Mount Sinai Hospital 14th on its elite Honor Roll of the nation's top hospitals based on reputation, safety, and other patient-care factors. Mount Sinai is one of just 12 integrated academic medical centers whose medical school ranks among the top 20 in NIH funding and by U.S. News & World Report and whose hospital is on the U.S. News & World Report Honor Roll. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 560,000 outpatient visits took place.

For more information, visit http://www.mountsinai.org/. Find Mount Sinai on: Facebook: http://www.facebook.com/mountsinainyc Twitter @mountsinainyc YouTube: http://www.youtube.com/mountsinainy

ELSE PRESS RELEASES FROM THIS DATE:

Older adults benefit from home-based DVD exercise program

2013-03-11

CHAMPAIGN, Ill. — Fitness DVDs are a multimillion-dollar business, and those targeting adults over the age of 55 are a major part of the market. With names like "Boomers on the Move," "Stronger Seniors" and "Ageless Yoga," the programs promise much, but few have ever been rigorously tested. "There are tons of DVDs out there, 20 percent of them are purchased by older adults, and with few exceptions there is no evidence that they work," said University of Illinois kinesiology and community health professor Edward McAuley, who led a new study testing the efficacy of a home-based ...

Tiny piece of RNA keeps 'clock' running in earliest stages of life

2013-03-11

COLUMBUS, Ohio – New research shows that a tiny piece of RNA has an essential role in ensuring that embryonic tissue segments form properly. The study, conducted in chicken embryos, determined that this piece of RNA regulates cyclical gene activity that defines the timing of the formation of tissue segments that later become muscle and vertebrae. Genes involved in this activity are turned on and off in an oscillating pattern that matches the formation of each tissue segment. If the timing of these genes' activity doesn't remain tightly regulated, the tissue either won't ...

International conference to tackle climate-change threats to agriculture

2013-03-11

Scientists and policymakers from around the world will gather March 20-22 at the University of California, Davis, to grapple with the threats of climate change for global agriculture and recommend science-based actions to slow its effects while meeting the world's need for food, livelihood and sustainability. The Climate-Smart Agriculture Global Science Conference, planned in coordination with the World Bank, builds on a 2011 international meeting on this theme in the Netherlands. "Climate change, which brings severe weather events and more subtle but equally menacing ...

Fluoride in drinking water cuts tooth decay in adults

2013-03-11

A new study conducted by researchers at the University of North Carolina at Chapel Hill and the University of Adelaide, Australia, has produced the strongest evidence yet that fluoride in drinking water provides dental health benefits to adults, even those who had not received fluoridated drinking water as children. In the first population-level study of its kind, the study shows that fluoridated drinking water prevents tooth decay for all adults regardless of age, and whether or not they consumed fluoridated water during childhood. Led by UNC School of Dentistry faculty ...

Nonprofits a major source of employment growth globally

2013-03-11

A new report from the Johns Hopkins Institute for Policy Studies reveals that nonprofit organizations are major employers and major sources of employment growth in countries throughout the world. The report draws on new data generated by statistical offices in 16 countries that have implemented a new United Nations Handbook on Nonprofit Institutions. This Handbook calls on national statistical offices to report on the economic scale and composition of nonprofit organizations in their countries for the first time. Key findings to date from implementation of this Handbook, ...

A new drug reduces heart damage

2013-03-11

This press release is available in French. A single dose of an investigational anti-inflammatory drug called inclacumab considerably reduces damage to heart muscle during angioplasty (the opening of a blocked artery), according to a recent international clinical trial spearheaded by Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, affiliated with the University of Montreal. Presented today in San Francisco at the prestigious American cardiology conference, these findings show great promise. "Inclacumab could indeed become an ...

Significant reduction in temperature and vegetation seasonality over northern latitudes

2013-03-11

An international team of authors from 17 institutions in seven countries, including the Woods Hole Research Center, published a study in the journal Nature Climate Change on the 10 March 2013 (10.1038/NCLIMATE1836: http://www.nature.com/nclimate). The study shows that, as the cover of snow and ice in the northern latitudes has diminished in recent years, the temperature over the northern land mass has increased at different rates during the four seasons, causing a reduction in temperature and vegetation seasonality in this area. The temperature and vegetation at northern ...

Can hormone help treat multiple sclerosis long-term?

2013-03-11

SAN DIEGO – A new study suggests that treatment with adrenocorticotropic hormone (ACTH) may be helpful for people whose multiple sclerosis (MS) is not well-controlled through their regular treatment. The study was released today and will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013. The study involved 23 people with MS who were taking beta-interferon treatment and had at least one relapse or brain scan showing new disease activity within the previous year. They were considered to have "breakthrough" MS, which ...

Early detection of MS treatment complication may improve survival

2013-03-11

SAN DIEGO – The drug natalizumab is effective for treating multiple sclerosis (MS), but it increases the risk of a rare but potentially fatal brain infection called progressive multifocal leukoencephalopathy (PML). A study released today that will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013, suggests that early detection of PML may help improve survival and disability levels. The study examined 319 people with MS who were treated with natalizumab and diagnosed with PML. Because of the risk of PML, people ...

Amplified greenhouse effect shaping North into South

2013-03-11

BOSTON—An international team of 21 authors from 17 institutions in seven countries has just published a study in the journal Natural Climate Change showing that, as the cover of snow and ice in the northern latitudes has diminished in recent years, the temperature over the northern land mass has increased at different rates during the four seasons, causing a reduction in temperature and vegetation seasonality in this area. In other words, the temperature and vegetation at northern latitudes increasingly resembles those found several degrees of latitude farther south as ...

Combination therapy provides similar clinical benefit as single drug treatment in MS

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: